In the corrugated-iron settlements ringing Johannesburg, in the migrant dormitories of Mumbai, in the prisons of Eastern Europe and the highland villages of Peru, an ancient pathogen continues its patient work. Mycobacterium tuberculosis killed approximately 1.5 million people last year—more than HIV, more than malaria, more than any other single infectious agent. This is a disease we know how to cure. Effective treatment has existed for over seventy years. And yet the body count rises.

The persistence of tuberculosis constitutes one of global health's most damning indictments. Unlike emerging pathogens that catch the world flat-footed, TB is thoroughly understood: its transmission dynamics, its bacteriology, its pharmacological vulnerabilities. What we lack is not knowledge but the political economy to deploy that knowledge where it matters most. The disease has become, in Paul Farmer's memorable framing, a biological expression of social inequality.

Understanding why TB endures requires stepping beyond the biomedical model. It demands examining how poverty creates the ecological conditions for transmission, how six-month treatment regimens collide with the material realities of daily wage labor, and how the HIV pandemic transformed a slowly retreating disease into a resurgent killer. These structural forces—not any deficiency in our therapeutic arsenal—explain why a curable illness remains civilization's most lethal infection.

Tuberculosis is often described as a disease of poverty, but that phrase obscures more than it reveals. TB does not simply correlate with deprivation; it is produced by it through specific, identifiable mechanisms. Crowded housing multiplies transmission opportunities. Indoor air pollution from biomass cooking fuels damages pulmonary defenses. Malnutrition suppresses cell-mediated immunity, allowing latent infection to progress to active disease. Diabetes, silicosis, and alcohol use disorders—all epidemiologically clustered in low-income populations—compound the risk.

The ecology of transmission is stark. A single untreated case can infect ten to fifteen contacts per year in high-burden settings. In South African gold mines, where miners work in poorly ventilated shafts breathing silica dust, TB incidence has reached levels comparable to the pre-antibiotic era. The pathogen exploits the built environment of extraction economies with remarkable efficiency.

But the arrow runs in both directions. TB does not merely reflect poverty—it deepens it. Patients lose an average of three to four months of income during treatment. Catastrophic health expenditures, defined as costs exceeding twenty percent of annual household income, affect nearly half of TB-affected families in low-income countries despite nominally free treatment. Transportation, food supplementation during therapy, and lost wages accumulate into economic devastation.

This bidirectional relationship creates what health economists call a poverty trap. Households impoverished by illness cannot afford the nutritional recovery and housing improvements that would prevent recurrence. Children pulled from school to work when a parent falls ill lose the educational trajectory that might have moved them beyond the exposure environment. The disease reproduces the very conditions that enabled it.

Effective TB control, therefore, cannot be reduced to case-finding and drug provision. It requires cash transfers, nutritional support, housing improvements, and workplace protections. Countries that have made genuine progress—Brazil's Bolsa Família recipients showed measurably better TB outcomes—have understood that biomedical intervention divorced from social protection is treating symptoms of a deeper pathology.

Takeaway

Diseases of poverty are not accidents of geography or misfortune—they are the biological register of structural violence, and their solutions must be equally structural.

Standard TB treatment requires six months of daily multi-drug therapy: isoniazid, rifampin, ethambutol, and pyrazinamide in the intensive phase, followed by four months of continuation. The regimen is highly effective—cure rates exceed 85 percent when completed. It is also, from the patient's perspective, an act of considerable endurance.

Symptoms typically resolve within weeks. Patients feel healthy long before their bacteriological cure is complete. Meanwhile, the drugs produce hepatotoxicity, peripheral neuropathy, gastrointestinal distress, and orange discoloration of bodily fluids. For a daily wage laborer in Bihar or a domestic worker in Manila, the calculus is brutal: continue medications that make you feel worse for months after you feel better, or return to earning a living.

Directly Observed Therapy, Short-course (DOTS), pioneered by Karel Styblo and adopted globally by WHO in the 1990s, addressed adherence through direct supervision of medication ingestion. The strategy achieved impressive results in some settings but has been criticized for placing the burden of surveillance on patients rather than addressing the structural obstacles to completion. Traveling to a clinic daily for six months is itself a luxury not everyone can afford.

Recent innovations show more promise. The BPaL regimen—bedaquiline, pretomanid, and linezolid—has reduced treatment for highly drug-resistant TB from 18-24 months to six months with dramatically better outcomes. The 4R regimen using rifapentine and moxifloxacin has demonstrated non-inferiority to six-month treatment in just four months. Digital adherence technologies, from pill bottles that record openings to video-observed therapy via smartphone, offer alternatives to physical supervision.

Yet regimen shortening, while necessary, is insufficient. The deepest adherence problem is not pharmacological but economic. Patients complete treatment when the material conditions of their lives permit it. Conditional cash transfers, food packages, and treatment support workers embedded in communities consistently outperform surveillance-based approaches. The question is not how to watch patients swallow pills, but how to make swallowing them compatible with survival.

Takeaway

Non-adherence is rarely a failure of patient discipline—it is a rational response to impossible choices, and interventions that ignore this reality are destined to disappoint.

Through the 1980s, tuberculosis was in slow retreat across much of the world. Incidence declined in Europe, North America, and parts of Latin America. Then HIV arrived, and the epidemiological ground shifted beneath us. Sub-Saharan Africa, particularly the southern cone, witnessed TB rates increase fivefold within a decade. In Eswatini and Lesotho, HIV-TB co-infection rates exceeded seventy percent among TB cases.

The biological mechanism is direct: HIV depletes CD4 T-cells, the immune sentinels that contain latent TB infection. A person with HIV faces roughly a twenty-fold increased risk of progression to active disease. The relationship is bidirectional—active TB accelerates HIV progression through chronic immune activation. Each infection worsens the trajectory of the other, exemplifying what medical anthropologist Merrill Singer termed a syndemic: the synergistic clustering of diseases within populations experiencing structural disadvantage.

Clinical management of co-infection presents formidable challenges. Drug interactions between rifamycins and certain antiretrovirals require regimen adjustments. Immune Reconstitution Inflammatory Syndrome can produce paradoxical worsening when antiretroviral therapy is initiated. Diagnostic difficulty compounds these problems—HIV-positive patients frequently present with paucibacillary disease or extrapulmonary manifestations that evade standard sputum-based testing.

Where TB and HIV programs remain administratively separate—as they long did in many national health systems—patients fall through the gaps. Integration has produced dramatic gains. South Africa's routine HIV testing of TB patients and universal antiretroviral initiation transformed outcomes within a decade. Rwanda's decentralized integrated model demonstrated what is possible when co-infection is treated as a single clinical entity rather than two overlapping problems.

The syndemic framework has implications beyond TB and HIV. Diabetes-TB, mental illness-substance use, and undernutrition-infectious disease clusters all demand integrated responses. The vertical disease programs that dominated twentieth-century global health, each with its own funding stream and metrics, are increasingly recognized as poorly matched to the actual burden patients carry. The future belongs to horizontal, patient-centered systems that treat people rather than pathogens.

Takeaway

Diseases do not respect the categorical boundaries that health systems impose on them—the pathologies of the poor arrive in bundles, and effective care must be equally integrated.

Tuberculosis endures not because it defeats our science but because it exposes our priorities. The tools to eliminate it exist. What is missing is the sustained political commitment to deploy them at scale, to fund the social protections that make treatment completion possible, and to address the housing, nutrition, and workplace conditions that generate transmission.

The countries making genuine progress—Peru's DOTS-Plus program, Brazil's integrated social protection, Rwanda's decentralized care model—share a recognition that TB control is inseparable from development. They treat the disease as a symptom of broader inequalities rather than a discrete biomedical problem.

For those working in global health, TB offers a sobering lesson: technical solutions without political solutions produce disappointing results. The pathogen has been patient for millennia. Whether we match that patience with the systemic commitments required to finally end its reign is the question our generation will answer.